Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Double-Blind Placebo-Controlled Study of Nedosiran in Primary Hyperoxaluria (Japan)
jRCT2080225181Phase 2Completed
- Sponsor
- Dicerna Pharmaceuticals, Inc., Inc. (ICCC: intellim Corporation)
- Start
- Apr 2020
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in Primary hyperoxaluria (PH) comparing Nedosiran with Placebo (2 arms). Started Apr 2020; status: completed.
02
Drugs
nedosiran
03
Conditions
Primary hyperoxaluria (PH)
Beyond the preview
Go deeper on jRCT2080225181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225181.